Paper of the MonthFeatured Slider
Paper of the month: Edaravone reduces disability progression in early ALS
or August 2017, we have selected: The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505-512.
There is evidence that oxidative stress induced by free radicals is a key factor of progression in amyotrophic lateral sclerosis (ALS).

Memories from the 3rd EAN Congress in Amsterdam
find yourself, a colleague or a friend in the
Amsterdam photo-gallery
Amsterdam 2017: Memories from the 3rd EAN Congress – view the photo gallery was last modified: July 31st,…
Amsterdam, 26 June 2017 – The Congress of the European Academy of Neurology (EAN) in Amsterdam received a royal visit today: H.M. Queen Máxima of the Netherlands attended the major scientific event at RAI Amsterdam, in which over 6,000 people…
by Catharina G. Faber
Neuromuscular Centre the Netherlands
The field of neuromuscular diseases in the Netherlands is characterized by a longstanding tradition of collaboration between seven neuromuscular centres of the university hospitals. This collaboration has been formalised since 1993, when…